Similar articles for PMID: 10619855

Year	Number of Results
2000	1
2001	2
2002	1
2003	1
2004	3
2005	2
2006	1
2007	6
2008	6
2009	8
2010	8
2011	1
2012	2
2024	0

1

Anticancer drug targets: growth factors and growth factor signaling.

Gibbs JB. Gibbs JB. J Clin Invest. 2000 Jan;105(1):9-13. doi: 10.1172/JCI9084. J Clin Invest. 2000. PMID: 10619855 Free PMC article. Review. No abstract available.

2

The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.

Motoyama AB, Hynes NE, Lane HA. Motoyama AB, et al. Cancer Res. 2002 Jun 1;62(11):3151-8. Cancer Res. 2002. PMID: 12036928

3

Anti-epidermal growth factor receptor strategies for advanced breast cancer.

Campos SM. Campos SM. Cancer Invest. 2008 Oct;26(8):757-68. doi: 10.1080/07357900801971040. Cancer Invest. 2008. PMID: 18853311 Review. No abstract available.

4

Foreword.

Chen HX, Cleck JN, Coelho R, Dancey JE. Chen HX, et al. Curr Probl Cancer. 2009 Jul-Aug;33(4):244. doi: 10.1016/j.currproblcancer.2009.10.001. Curr Probl Cancer. 2009. PMID: 20082841 No abstract available.

5

Antitumor activity of a dual epidermal growth factor receptor and ErbB2 kinase inhibitor MP-412 (AV-412) in mouse xenograft models.

Suzuki T, Fujii A, Ohya J, Nakamura H, Fujita F, Koike M, Fujita M. Suzuki T, et al. Cancer Sci. 2009 Aug;100(8):1526-31. doi: 10.1111/j.1349-7006.2009.01197.x. Epub 2009 May 13. Cancer Sci. 2009. PMID: 19459856 Free article.

6

AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.

Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T, Tang C, Wartmann M, Wood J, Caravatti G. Traxler P, et al. Cancer Res. 2004 Jul 15;64(14):4931-41. doi: 10.1158/0008-5472.CAN-03-3681. Cancer Res. 2004. PMID: 15256466

7

The HER3/ErbB3 receptor: a promising target in cancer drug therapy.

Desbois-Mouthon C. Desbois-Mouthon C. Gastroenterol Clin Biol. 2010 Apr-May;34(4-5):255-9. doi: 10.1016/j.gcb.2010.03.002. Epub 2010 Apr 24. Gastroenterol Clin Biol. 2010. PMID: 20418034 Free article. No abstract available.

8

Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity.

Mahboobi S, Sellmer A, Winkler M, Eichhorn E, Pongratz H, Ciossek T, Baer T, Maier T, Beckers T. Mahboobi S, et al. J Med Chem. 2010 Dec 23;53(24):8546-55. doi: 10.1021/jm100665z. Epub 2010 Nov 16. J Med Chem. 2010. PMID: 21080629

9

Design, synthesis and biological evaluation of pyrazolyl-thiazolinone derivatives as potential EGFR and HER-2 kinase inhibitors.

Qiu KM, Wang HH, Wang LM, Luo Y, Yang XH, Wang XM, Zhu HL. Qiu KM, et al. Bioorg Med Chem. 2012 Mar 15;20(6):2010-8. doi: 10.1016/j.bmc.2012.01.051. Epub 2012 Feb 4. Bioorg Med Chem. 2012. PMID: 22361272

10

Design, synthesis and biological evaluation of thiazolidinone derivatives as potential EGFR and HER-2 kinase inhibitors.

Lv PC, Zhou CF, Chen J, Liu PG, Wang KR, Mao WJ, Li HQ, Yang Y, Xiong J, Zhu HL. Lv PC, et al. Bioorg Med Chem. 2010 Jan 1;18(1):314-9. doi: 10.1016/j.bmc.2009.10.051. Epub 2009 Oct 30. Bioorg Med Chem. 2010. PMID: 19914835

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

37 results

Results by year